Alagille syndrome is a multisystem disorder classically involving the liver, heart, vertebrae, facial features, and the eyes. In this case report, we document a case of Alagille syndrome with an atypical clinical and histopathologic presentation and subsequent identification of a novel JAG1 missense mutation. This case highlights that there may be both atypical clinical and pathologic findings in mutation-proven Alagille syndrome and that the diagnosis of Alagille syndrome should be considered in cases of ongoing bile duct damage in the setting of early-onset jaundice, cholestasis, hepatosplenomegaly, posterior embryotoxon in the eyes, and butterfly vertebrae.
Introduction
Alagille syndrome occurs in 1 in 30,000 to 50,000 live births. 1 Typical features include cholestasis, cardiac defects, butterfly vertebrae, posterior embryotoxon in the eyes, and characteristic facial features. The majority of cardiac defects involve some degree of pulmonary stenosis. 2, 3 The classic histologic feature in Alagille syndrome is a paucity of interlobular bile ducts, defined as presence of a bile duct in less than 50% of evaluable portal tracts. 4 This paucity may not be identified in early biopsies, but is present by one year of age in the vast majority of patients. 3 Additional histologic findings include bile duct proliferation, bile duct degeneration, intrahepatic cholestasis, and giant cell hepatitis. 3, 5 Portal fibrosis, with or without bridging, may be seen in later stages of the disease. 6 Histologic findings are used in combination with clinical and genetic findings to diagnose Alagille syndrome.
Alagille syndrome is an autosomal-dominant disorder with variable expressivity and penetrance. 1 In most cases, Alagille syndrome is caused by a mutation in the JAG1 gene on chromosome 20p12 that encodes for a cell surface ligand, JAGGED 1. 1 This ligand interacts with the Notch receptor. 1 Thus, a mutation in JAG1 resulting in haploinsufficiency disrupts the Notch signaling pathway and in turn, disrupts embryologic development. 7 As JAG1 is also prominently expressed in vasculature, the paucity of intrahepatic bile ducts may be due to poor development of intrahepatic arterial branches. 7 In addition, JAG1 signaling is important in expansion of the portal vein mesenchyme and in regulation of bile duct development. 7 The effects of disruption in this signaling are seen in features of Alagille syndrome.
life and was started on ursodiol. At 3 months of age, his liver enzymes were elevated to the following: AST 385, ALT 303, alkaline phosphatase 651, gamma-glutamyl transpeptidase (GGT) 1430, and total bilirubin of 10.1 with a direct bilirubin of 5.9. Ultrasound at this time did not identify a dilated common bile duct or a dilated hepatic duct. In fact, no bile ducts were seen. The gallbladder was described as contracted. Liver biopsy at 3 months of age showed abundant cholestasis with a neonatal hepatitis pattern of injury. The lobular architecture was distorted by portal and lobular hepatitis composed predominantly of lymphocytes, with giant cell transformation of hepatocytes and lobular disarray. There was no significant iron accumulation. Portal tracts were expanded by fibrosis, but no bridging was noted. There was no bile ductular proliferation, but of note, in this biopsy specimen, bile ducts were overall difficult to identify as they may have been damaged. It was difficult to determine whether the damaged appearance was due to extensive crush artifact or due to bile duct paucity. As this first biopsy was an outside hospital consult, bile duct to portal tract ratio and CK7 staining were not obtained and are not available. The pattern seen on the biopsy was not consistent with extrahepatic biliary obstruction.
Differential diagnosis at this point included neonatal hepatitis, multidrug resistance protein 3 (MDR3) deficiency, mitochondrial disorders, and cholestasis from metabolic disorders, such as disorders of bile acid metabolism.
The patient's jaundice resolved around 7 months of age, but he continued to have hepatomegaly, splenomegaly, severe pruritus, and a 2/6 systolic heart murmur, which was benign as he had a normal EKG and a normal ECHO. He never developed scleral icterus, GI bleeding, cholangitis, easy bruising, xanthomas, ascites, acholic stools, or neurological symptoms. His weight tracked along the 50th to 60th percentile and height tracked along the 40th percentile.
Liver enzymes trended downwards as he got older. Laboratory workup was negative for the more common inherited disorders, metabolic and storage disorders, viral hepatitis, and autoimmune hepatitis. Peripheral blood counts, coagulation factors, electrolytes, and vitamin levels were within normal limits.
A second liver biopsy was done at 15 months of age when the patient had the following liver enzymes: AST 301, ALT 318, alkaline phosphatase 1141, and total bilirubin of 1.0. The biopsy showed focal portal fibrous expansion, minimal lobular inflammation, and focal interface hepatitis. Previous features of neonatal hepatitis were not seen on this biopsy. Within the fibrotic portal tracts, there were numerous ductular structures with irregular outlines and a few normal-appearing interlobular bile ducts with well-formed lumens, highlighted by cytokeratin 7 (CK7) immunohistochemical staining ( Figure 1 ). In this biopsy, there were a total of 7 portal tracts counted, and 4 of them had bile ducts, resulting in a bile duct to portal tract ratio of 0.57. Additionally, approximately 50%-60% of the hepatocytes showed aberrant staining for CK7. The hepatocytes were negative for intracytoplasmic iron, copper, and PAS-positive inclusions. Electron microscopy did not identify any mitochondrial abnormalities or storage material collections.
Based on the histologic findings at this point, an obstructive cholangiopathy was possible. The differential of obstructive cholangiopathy included an ongoing sclerosing cholangitis, MDR3 deficiency, Langerhan's cell histiocytosis (LCH), and other causes of bile duct loss or injury. The most recent biopsy did not stain positive for S-100 or CD1a, making LCH less likely. The biopsy had retained MDR3 staining in the bile canaliculi, reducing the likelihood of MDR3 deficiency, also known as progressive familial intrahepatic cholestasis (PFIC) type 3. Aberrant hepatocyte staining for CK7 has been associated with cholestatic diseases with loss of interlobular bile ducts, such as extrahepatic biliary atresia and Alagille syndrome, supporting the possibility of an evolving bile duct paucity.
At 18 months of age, an MRCP was done given evidence of bile duct injury on pathology and question of neonatal sclerosing cholangitis. MRCP showed an enlarged liver with heterogeneous parenchyma and mild periportal fibrosis. No intrahepatic biliary ductal dilatation, focal beading, associated ascites, or collateral vessels were noted. At 18 months of age, a skeletal survey was performed and was normal. There were no Langerhans cell histiocytosis or vertebral body abnormalities noted on the skeletal survey.
At 3 years of age, an ultrasound of the abdomen showed an enlarged liver measuring 10.5 cm in length at the right hepatic lobe. No focal hepatic lesions, pericholecystic fluid, or gross intrahepatic biliary ductal dilatation were identified. The gallbladder was normal, the main portal vein was patent, with flow in the appropriate direction, and the pancreatic head and body were normal in size and echogenicity. A third liver biopsy was done at 4 years of age when the patient had the following liver enzymes: AST 135, ALT 84, alkaline phosphatase 802, GGT 2024, and total bilirubin of 2.3, with a conjugated bilirubin of 0.5. Biopsy features included bridging portal fibrosis, focal mild mixed portal inflammation, and focal hepatocyte necrosis without lobulitis. Approximately 20% of evaluable portal tracts lacked a bile duct (Figure 2 ). There were a total of 9 portal tracts counted, and 7 of them had bile ducts, resulting in a bile duct to portal tract ratio of 0.78. The remaining bile ducts and ductules had irregular contours and appeared damaged and reactive (Figure 2) . Again, there was aberrant CK7 expression in approximately half of the hepatocytes (Figure 2 ). There was focal copper accumulation in periportal hepatocytes. Immunohistochemical staining was performed for GGT-1, MDR3, and CD13 on the current and most recent previous biopsies and showed retained canalicular staining in both, decreasing the likelihood of PFIC type 3. The differential diagnosis at this point in time again included an obstructive cholangiopathy. Sclerosing cholangitis, an inherited cholestatic disease, or an evolving bile duct paucity were possible.
At 4 years of age, a chest X-ray showed possible butterfly vertebra or forme fruste butterfly vertebra at T10 (Figure 3 ). Butterfly vertebrae are most easily recognized in older children. 8 Repeat MRCP and ultrasound at 4 years of age were stable. At 5 years of age, he was referred to an ophthalmologist because of atypical findings on liver biopsies thus far, and he was diagnosed with posterior embryotoxon in the eyes. Genetic testing found no mutations in ABCB4, indicating no PFIC 3 or MDR3 deficiency. JAG1 testing showed that he did not have a known disease-causing point mutation, deletion, or duplication within the coding region or intron/exon junctions of the JAG1 gene. However, he was heterozygous for a C to T base change at nucleotide 601 in exon 4 of the JAG1 gene (c.601C > T) that changed arginine (CGC) to cysteine (TGC) at amino acid position 201 (p.Arg201Cys), consistent with a missense mutation. Maternal genetic testing was negative for this specific missense mutation. Given this mutation in the JAG1 gene, Alagille syndrome was diagnosed in this child.
Discussion
In Alagille syndrome, cholestasis is reported in 96% of patients, cardiac murmur in 97% of patients, butterfly vertebrae in 51% of patients, characteristic facies in 96% of patients, and posterior embryotoxon in the eyes in 78% of patients. 2 Of the patients that have a cardiac murmur, 67% have stenosis at some level of the pulmonary tree and 16% have Tetralogy of Fallot.
2 Butterfly vertebrae result from persistent notochordal tissue between the anterior vertebral arches, causing failure of fusion of the arches. 2 The characteristic facies of Alagille is a triangular-shaped face with a prominent forehead, hypertelorism, deep-set eyes, a pointed chin, and a bulbous-tipped nose.
2 All 5 features of liver, heart, vertebral, facial, and eye involvement are present in 25% of patients, 4 features are present in 53% of patients, and 3 features are present in 22% of patients. 2, 3 Our patient only had 3 out of the 5 classical features of Alagille, with cholestasis, butterfly vertebra, and posterior embryotoxon in the eyes.
Our patient underwent 3 biopsies over a course of 4 years. The initial biopsy at 3 months of age showed a neonatal hepatitis pattern with possible bile duct damage, and overall evaluation was limited by extensive crush artifact. A second biopsy at 15 months of age showed resolution of the neonatal hepatitis, mild portal inflammation with mild interface activity, and lobulitis. Bile duct damage and portal fibrosis were present without bile duct paucity. There was also aberrant CK7 expression in a large proportion of the hepatocytes. A repeat biopsy at 4 years of age showed increased portal fibrosis with bridging and decreased inflammation. The bile ducts again appeared damaged and approximately 20% of portal tracts lacked bile ducts. The CK7 expression pattern in this third biopsy was similar to that in the second biopsy.
This case is atypical for Alagille syndrome in that even at 4 years of age, our patient did not have paucity of bile ducts to the extent defined in the literature. The normal bile duct to portal tract ratio is 0.9-1.8 and paucity of intralobular bile ducts is defined as a ratio of less than 0.5. 9 Alagille syndrome usually presents with presence of a bile duct in less than 50% of evaluable portal tracts. 4 This severe bile duct paucity is present in 50% of infants younger than 6 months old and in 95% of infants older than 6 months. 3 When this patient was 4 years of age, only 20% of his portal tracts lacked bile ducts. Although this patient has not developed extensive bile duct paucity, his bile ducts have been abnormal throughout his disease course, with degenerative and reactive changes since birth.
Notably, liver biopsies in young infants with Alagille are difficult to interpret due to ductal proliferation in the neonatal period. 9 In addition, the bile duct to portal tract ratio may be physiologically lower in premature infants. 10 Thus, identification of a JAG1 mutation is important in the diagnosis of Alagille syndrome. There have been case reports in which patients have had clinical features consistent with Alagille, with facial dysmorphism, conjugated hyperbilirubinemia, pulmonary stenosis, and posterior embryotoxon in the eyes, but did not have a detectable mutation in the JAG1 gene and were not diagnosed with Alagille syndrome. Interestingly, the diagnosis that one of these patients had was Williams syndrome.
The most recent biopsy showed increased fibrosis with bridging, suggesting histologic progression of his disease. After the JAG1 mutation was identified and the diagnosis confirmed, his biopsies were reviewed and a CD10 (neutral endopeptidase) immunostain was performed on the most recent biopsy, showing loss of canalicular CD10 staining. Canalicular CD10 expression is physiologically absent in infants but should be expressed by age 4 in a normal liver. 11 Although not entirely specific, absence of canalicular staining has been reported in Alagille syndrome and may be a useful diagnostic tool.
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Also of interest is the CK7 expression pattern seen in the second and third biopsies. Aberrant CK7 expression in hepatocytes has been described in a number of cholestatic diseases and is thought to represent metaplastic change. 12 A study of CK7 expression in pediatric liver disease showed a strong correlation between aberrant CK7 expression in hepatocytes and loss of interlobular bile ducts, regardless of disease etiology. 12 The strong expression of CK7 seen in our case suggests that a degree of bile duct paucity was likely present early in the disease course, though not seen in the early biopsies, which may represent a sampling error of the biopsies. The other possibility is that the bile duct damage seen throughout the disease course was sufficient to cause hepatocyte changes, though CK7 expression in cases of bile duct damage without paucity has not been investigated in the pediatric population.
Alagille syndrome is an autosomal-dominant disorder with variable expressivity and 84% penetrance. 7 About 60% of mutations are de novo and 8% are due to germline mosaicism.
2 Ninety-four percent of the time, Alagille syndrome is caused by a mutation in the JAG1 gene on chromosome 20p12. 1 One to two percent of the time, Alagille syndrome is caused by mutations in NOTCH2 on chromosome 1p13. 2 No mutation is identified 4.5% of the time. 1 Higher mutation rates are observed in patients with more classical features of Alagille syndrome. 13 Over 440 different JAG1 gene mutations and 10 NOTCH mutations have been identified in Alagille patients. 14 Of the JAG1 mutations, 49% are frameshift, 16% are nonsense, 15% are missense, 11% are gross deletions or insertions, and 9% are splice site mutations.
14 There is no apparent correlation between genotype and phenotype. 14 Our patient is the first case of Alagille syndrome who is heterozygous for a C to T base change at nucleotide 601 of the JAG1 gene (c.601C > T), resulting in a missense mutation that changes arginine (CGC) to cysteine (TGC) at amino acid position 201 (p.Arg201Cys). This mutation has not been reported previously in patients with Alagille syndrome, and its significance is not known with certainty. However, it is potentially disease-causing for the following reasons: (1) it is not a known polymorphism, (2) it results in a non-conservative amino acid substitution with a large physiochemical difference, (3) it alters an amino acid that is evolutionarily conserved from mammals to fish, (4) it occurs in the DSL (Delta/Serrate/Lag-2) domain that is highly conserved among all Notch ligands and important to the Notch signaling pathway, and (5) this variant is predicted to be deleterious or disease causing by 3 in silico mutation prediction algorithms (i.e., SIFT, MutationTaster, and Align-GVGD). However, in the absence of a functional assay, the significance of this variant cannot be known with certainty. [15] [16] [17] On presentation to us and prior to the diagnosis of Alagille, key differential diagnoses included PFIC3, primary sclerosing cholangitis, and Langerhans cell histiocytosis. PFIC3 was a possibility given the high GGT, but genetic testing with a normal ABCB4 gene ruled it out. 18 Primary sclerosing cholangitis was ruled out with a MRCP that did not show intrahepatic biliary ductal dilatation or focal beading. Our patient did not have S-100 or CD1a staining on liver biopsy, making LCH unlikely. [19] [20] [21] Our patient with Alagille syndrome has done well so far. He is currently 6 years old with well-compensated cirrhosis, normal hepatic synthetic function, and good growth. He has pruritus that is managed with ursodiol and hydroxyzine. He has evidence of portal hypertension with mild splenomegaly but no significant hypersplenism. This case highlights the fact that there may be both atypical clinical and pathologic findings in mutation-proven Alagille syndrome and that the diagnosis of Alagille syndrome should be considered in cases of ongoing bile duct damage in the setting of early-onset jaundice, cholestasis, hepatosplenomegaly, posterior embryotoxon in the eyes, and butterfly vertebrae.
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